In 2005 it was discovered that NSCLC cells with wild-type EGFR display a range of sensitivities to erlotinib, and that sensitivity depends on whether the cells express CDH1 or VIM [19]. The gene discussed is CDH1; the disease is non-small cell lung carcinoma.